Tornier NV PT Raised to $26.00 at Piper Jaffray (TRNX)
Piper Jaffray increased their price objective on shares of Tornier NV (NASDAQ:TRNX) from $25.00 to $26.00 in a research note issued on Friday. Piper Jaffray’s target price would suggest a potential upside of 19.65% from the company’s current price.
Shares of Tornier NV (NASDAQ:TRNX) traded up 11.49% during mid-day trading on Friday, hitting $21.73. 541,015 shares of the company’s stock traded hands. Tornier NV has a 52-week low of $15.17 and a 52-week high of $24.35. The stock’s 50-day moving average is $22.29 and its 200-day moving average is $20.51. The company’s market cap is $1.055 billion.
Tornier NV (NASDAQ:TRNX) last released its earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the analysts’ consensus estimate of ($0.16) by $0.04. The company had revenue of $86.85 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter last year, the company posted ($0.28) earnings per share. Tornier NV’s revenue was up 11.2% compared to the same quarter last year. On average, analysts predict that Tornier NV will post $-0.45 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. raised their price target on shares of Tornier NV from $20.00 to $23.00 in a research note on Friday. Separately, analysts at Barclays raised their price target on shares of Tornier NV from $26.00 to $28.00 in a research note on Friday. Finally, analysts at BMO Capital Markets upgraded shares of Tornier NV from a “market perform” rating to an “outperform” rating in a research note on Friday. They now have a $24.00 price target on the stock, up previously from $20.00. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $22.67.
Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.
Receive News & Ratings for Tornier NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tornier NV and related companies with Analyst Ratings Network's FREE daily email newsletter.